| JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
92%
|
Pursuant to the Purchase Agreement and related ancillary agreements, in consideration for the Transferred Assets, Jazz paid to the Company upfront consideration of $21.0 million, and has agreed to pa… |
| JAZZ |
Jazz Pharmaceuticals plc |
90%
|
Reciprocal relationship from JAZZ graph: Reciprocal relationship from HOWL graph: Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been desig… |
| JAZZ |
Jazz Pharmaceuticals plc |
90%
|
Jazz acquired exclusive global development and commercialization rights to WTX-613, which has subsequently been designated JZP898, as well as products containing certain isolated recombinant polypept… |
| ASND |
Ascendis Pharma A/S |
72%
|
Reciprocal relationship from ASND graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in co… |
| ASND |
Ascendis Pharma A/S |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| BMY |
Bristol-Myers Squibb Company |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| BMYMP |
Bristol-Myers Squibb Co |
72%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in c… |
| CELG-RI |
CELG-RI |
72%
|
Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from … |
| CELG-RI |
CELG-RI |
72%
|
, the court held that actions to challenge a federal regulation under the APA can be initiated within six years of the date of injury to the plaintiff, rather than the date the rule is finalized. The… |
| CUE |
Cue Biopharma, Inc. |
72%
|
Reciprocal relationship from CUE graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| CUE |
Cue Biopharma, Inc. |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| MRK |
Merck & Co., Inc. |
72%
|
Reciprocal relationship from MRK graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| MRK |
Merck & Co., Inc. |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from HOWL graph: Reciprocal relationship from MYGN g… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
Reciprocal relationship from TKPHF graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in c… |
| TKPHF |
Takeda Pharmaceutical Company Limited |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| XLO |
Xilio Therapeutics, Inc. |
72%
|
dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in connection with creating an independent sales and marketing organization. Developing… |
| XLO |
Xilio Therapeutics, Inc. |
72%
|
Reciprocal relationship from XLO graph: Reciprocal relationship from HOWL graph: dequate numbers of physicians to prescribe our product candidates, as well as any unforeseen costs we may incur in con… |
| ANKURA-TRUST-COMPANY-LLC |
ANKURA-TRUST-COMPANY-LLC |
62%
|
and 2025 was $0.7 million and $0.2 million, respectively, and primarily consisted of the gains recognized for the change in fair value of the derivative liability associated with the K2HV Loan Agreem… |
| ARE-770-784-790-MEMORIAL-DRIVE-LLC |
ARE-770-784-790-MEMORIAL-DRIVE-LLC |
62%
|
cules, or any future product candidates if we receive marketing approval, including marketing, sales and distribution costs; • the potential emergence of competing therapies and other adverse market … |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
listing of our common stock. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have an initial period of 180 calendar days, which expires on August 3, 2026, to regain compliance with the bid r… |
| HARPOON-THERAPEUTICS-INC |
HARPOON-THERAPEUTICS-INC |
62%
|
we believe we have sufficient funds for our current or future operating plans. Our future capital requirements, both short-term and long-term, will depend on many factors, including: • the scope, pro… |
| K2-HEALTHVENTURES-LLC |
K2-HEALTHVENTURES-LLC |
62%
|
nt Expenses Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and inclu… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
and 2025 was $0.7 million and $0.2 million, respectively, and primarily consisted of the gains recognized for the change in fair value of the derivative liability associated with the K2HV Loan Agreem… |
| NASDAQ-STOCK-MARKET-LLC |
NASDAQ-STOCK-MARKET-LLC |
62%
|
made against us and defending a suit, regardless of its merit, could be costly and divert management’s attention. Business disruptions and unfavorable economic conditions could seriously harm our bus… |
| WEREWOLF-THERAPEUTICS-MASS-SECURITIES-INC |
WEREWOLF-THERAPEUTICS-MASS-SECURITIES-INC |
62%
|
; identifying potential product candidates; enhancing our intellectual property portfolio; undertaking research, preclinical studies, and clinical trials; and enabling manufacturing for our developme… |
